Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05923008RecruitingPhase 1/Phase 2
Study of IBI130 for advanced solid tumors
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Birtinya, QueenslandAges 18 years+ - NCT06246071RecruitingPhase 1
TYK-00540 for adults with solid tumors
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
HefeiAges 18 years+ - NCT06374173RecruitingPhase 1
Study of TGI-6 for advanced solid tumors
This study tests a new drug called TGI-6 in people with advanced solid tumors, including colorectal cancer and other cancers that have a specific marker (B7-H6). The goal is to see if it is safe and effective for those who have run out of standard treatment options.
BeijingAges 18 years+ - NCT06086522RecruitingPhase 1
Study of QN-302 for advanced solid tumors
This trial tests an experimental drug called QN-302 in people with advanced solid tumors that have grown despite standard treatments or for which no standard therapy exists. The goal is to see if it is safe and how the body processes it.
Scottsdale, ArizonaAges 18 years+ - NCT05693844RecruitingPhase 1/Phase 2
MSLN CAR T cell therapy for advanced solid tumors
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
Beijing, Beijing MunicipalityAges 18–75 - NCT07807241RecruitingPhase 1
Study of MX006 for advanced tumors with B7-H3
This trial tests a new drug (MX006) in people with advanced or metastatic tumors that have a specific marker called B7-H3. The drug may work by targeting this marker to stop cancer growth. The study aims to see if MX006 is safe and effective in this patient group.
Sarasota, FloridaAges 18 years+ - NCT07787208RecruitingPhase 1
Experimental drug for advanced solid tumors
This trial tests an investigational drug called ONO-7429 for people with advanced or recurrent solid tumors that have not responded to standard treatments. The goal is to see if the drug can help control the cancer.
Kashiwa, ChibaAges 18 years+ - NCT07753226RecruitingPhase 1
Study of SI-B036 for advanced breast cancer and other solid tumors
This study tests a new drug called SI-B036 for people with advanced breast cancer or other solid tumors that have spread. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18–75 - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+ - NCT07730021RecruitingPhase 1/Phase 2
New drug for advanced solid tumors
This trial tests a new drug called ASP388B, given alone or with standard treatments, for people with certain advanced solid tumors that have stopped responding to therapy. It may help shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06622486RecruitingPhase 1/Phase 2
EGL-001 for advanced solid tumors after immunotherapy
This trial tests a new drug called EGL-001 for people with advanced solid tumors that have already been treated with immunotherapy. The goal is to see if the drug is safe and effective against cancer that has not responded to other treatments.
DijonAges 18 years+ - NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07621471RecruitingEarly Phase 1
NK Cell Therapy Enhanced with IL-15 for Advanced Solid Tumors
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
ChongqingAges 18–70 - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07610798RecruitingPhase 1/Phase 2
Testing INV-8989 for Advanced Cancers With KRAS G12D Mutation
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07612189RecruitingPhase 1
Testing NEOK002 for Advanced Solid Tumors
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
Orlando, FloridaAges 18 years+ - NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
New York, New YorkAges 18 years+ - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.